Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone

Sebastian Mirkin, Shelli Graham, Dennis A Revicki, Randall H Bender, Brian Bernick, Ginger D Constantine, Sebastian Mirkin, Shelli Graham, Dennis A Revicki, Randall H Bender, Brian Bernick, Ginger D Constantine

Abstract

Objective: To characterize the impact of TX-001HR on the relationship between vasomotor symptom (VMS) improvement and quality of life and sleep.

Methods: REPLENISH (NCT01942668) was a phase 3, randomized, double-blind, placebo-controlled, multicenter trial, which evaluated four daily doses of 17β-estradiol and progesterone (E2/P4) combined in a single, oral, softgel capsule in postmenopausal women (40-65 years) with a uterus and moderate to severe VMS (≥7/day or ≥50/week). In post hoc analyses, growth models were used to examine relationships between linear changes in VMS frequency and severity over 12 weeks and changes from baseline in the Menopause-Specific Quality of Life (MENQOL; total score and VMS domain) and the Medical Outcomes Study-Sleep (total score, sleep problems indices I and II) questionnaire outcomes at 12 weeks with treatment compared with placebo.

Results: Outcomes with all four E2/P4 doses were combined (n = 591) and compared with placebo (n = 135). In all 5 growth models, the effects of TX-001HR on MENQOL total score and vasomotor domain were significantly associated with changes in VMS frequency and severity observed over 12 weeks (all, P < 0.001). Treatment-mediated effects on MENQOL via VMS frequency and severity models were significant. Similar results were found with Medical Outcomes Study-Sleep total score and sleep problems indices.

Conclusions: TX-001HR improvements in quality of life and sleep outcomes are associated with and may be mediated through improvements in VMS frequency and severity.

Figures

FIG. 1
FIG. 1
Relationship of treatment, hot flush frequency (Freq) and severity (Sev) changes, and changes in Menopause-Specific Quality of Life (MENQOL) questionnaire (A) overall; (B) vasomotor domain. ∗P < 0.05; †P < 0.01; ‡P < 0.001. Solid lines are statistically significant paths, dashed lines are not significant. Fixed cubic and quadratic (quad) terms were not included in the figures.
FIG. 2
FIG. 2
Relationship of treatment, hot flush frequency (Freq) and severity (Sev) changes, and changes in Medical Outcomes Study (MOS)-Sleep Scale (A) overall; (B) sleep problems index I; (C) sleep problems index II. ∗P < 0.05; †P < 0.01; ‡P < 0.001. Solid lines are statistically significant paths, dashed lines are not significant. Fixed cubic and quadratic (quad) terms were not included in the figures.

References

    1. Blumel JE, Chedraui P, Baron G, et al. A large multinational study of vasomotor symptom prevalence, duration, and impact on quality of life in middle-aged women. Menopause 2011; 18:778–785.
    1. Blumel JE, Cano A, Mezones-Holguin E, et al. A multinational study of sleep disorders during female mid-life. Maturitas 2012; 72:359–366.
    1. Whiteley J, Wagner JS, Bushmakin A, Kopenhafer L, Dibonaventura M, Racketa J. Impact of the severity of vasomotor symptoms on health status, resource use, and productivity. Menopause 2013; 20:518–524.
    1. Kleinman NL, Rohrbacker NJ, Bushmakin AG, Whiteley J, Lynch WD, Shah SN. Direct and indirect costs of women diagnosed with menopause symptoms. J Occup Environ Med 2013; 55:465–470.
    1. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes 2005; 3:47.
    1. Ayers B, Hunter MS. Health-related quality of life of women with menopausal hot flushes and night sweats. Climacteric 2013; 16:235–239.
    1. Hunter MS, Gentry-Maharaj A, Ryan A, et al. Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a cross-sectional cohort study of 10,418 British women aged 54-65. BJOG 2012; 119:40–50.
    1. Duffy OK, Iversen L, Hannaford P. The impact and management of symptoms experienced at midlife: a community-based study of women in northeast Scotland. BJOG 2012; 119:554–564.
    1. Savolainen-Peltonen H, Hautamaki H, Tuomikoski P, Ylikorkala O, Mikkola TS. Health-related quality of life in women with or without hot flashes: a randomized placebo-controlled trial with hormone therapy. Menopause 2014; 21:732–739.
    1. Ensrud KE, Stone KL, Blackwell TL, et al. Frequency and severity of hot flashes and sleep disturbance in postmenopausal women with hot flashes. Menopause 2009; 16:286–292.
    1. Lampio L, Polo-Kantola P, Polo O, Kauko T, Aittokallio J, Saaresranta T. Sleep in midlife women: effects of menopause, vasomotor symptoms, and depressive symptoms. Menopause 2014; 21:1217–1224.
    1. De Zambotti M, Colrain IM, Javitz HS, Baker FC. Magnitude of the impact of hot flashes on sleep in perimenopausal women. Fertil Steril 2014; 102:1708–1715.e1.
    1. Ohayon MM. Severe hot flashes are associated with chronic insomnia. Arch Intern Med 2006; 166:1262–1268.
    1. Williams RE, Levine KB, Kalilani L, Lewis J, Clark RV. Menopause-specific questionnaire assessment in US population-based study shows negative impact on health-related quality of life. Maturitas 2009; 62:153–159.
    1. Worsley R, Bell RJ, Gartoulla P, Robinson PJ, Davis SR. Moderate-severe vasomotor symptoms are associated with moderate-severe depressive symptoms. J Womens Health (Larchmt) 2017; 26:712–718.
    1. Lobo RA, Archer DF, Kagan R, et al. A 17β-estradiol–progesterone oral capsule for vasomotor symptoms in postmenopausal women: A randomized controlled trial. Obstet Gynecol 2018; 132:161–170.
    1. Simon JA, Kaunitz A, Kroll R, et al. Oral 17β-estradiol-progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms. Menopause 2019; 26:506–512.
    1. Kagan R, Constantine G, Kaunitz AM, Bernick B, Mirkin S. Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women. Menopause 2018; [In press].
    1. Hilditch JR, Lewis J, Peter A, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. Maturitas 1996; 24:161–175.
    1. Hays RD, Stewart AL. Stewart AL, Ware JE. Sleep measures. Measuring Functioning and Well-being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992. 235–259.
    1. Muthén LK, Muthén BO. Mplus User's Guide. Muthén and Muthén, Eighth ed.Los Angeles, CA: 1998-2017.
    1. Kravitz HM, Joffe H. Sleep during the perimenopause: a SWAN story. Obstet Gynecol Clin North Am 2011; 38:567–586.
    1. Pinkerton JV, Abraham L, Bushmakin AG, Cappelleri JC, Komm BS. Relationship between changes in vasomotor symptoms and changes in menopause-specific quality of life and sleep parameters. Menopause 2016; 23:1060–1066.
    1. Polo-Kantola P. Sleep problems in midlife and beyond. Maturitas 2011; 68:224–232.
    1. Montplaisir J, Lorrain J, Denesle R, Petit D. Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause 2001; 8:10–16.
    1. Gambacciani M, Ciaponi M, Cappagli B, et al. Effects of low-dose, continuous combined hormone replacement therapy on sleep in symptomatic postmenopausal women. Maturitas 2005; 50:91–97.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する